Q324 Financial Results November 6, 2024 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its anticipated full ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Daniel O'Day - Chairman, Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Jackie Ross - Vice President, Investor Relations, Corporate Strategic Finance Cindy Perettie - Executive Vice President of Kite Conference Call Participants Courtney Breen - Bernstein Mike Yee - Jeffries Umer Raffat - E ...

Gilead Sciences (GILD) reported $7.55 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 7%. EPS of $2.02 for the same period compares to $2.29 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $6.99 billion, representing a surprise of +7.94%. The company delivered an EPS surprise of +27.85%, with the consensus EPS estimate being $1.58. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings - ...

Gilead Sciences (GILD) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 27.85%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.61 per share when it actually produced earnings of $2.01, delivering a surprise of 24.84%. Over the last fou ...

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% Year-Over-Year to $816 million Foster City, CA, November 6, 2024 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead's third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including ...

The earnings season for the drug/biotech sector is now in its final lap, with some large biotech and generic drug companies due to report their third-quarter 2024 results this week.The remaining large drugmakers have already reported their results. Many of these companies beat estimates for both earnings and sales. While some like Pfizer and AbbVie raised their guidance ranges, others like Eli Lilly & Merck cut their outlook.Per the Zacks classification, the pharma/biotech industry comes under the broader M ...

The upcoming report from Gilead Sciences (GILD) is expected to reveal quarterly earnings of $1.58 per share, indicating a decline of 31% compared to the year-ago period. Analysts forecast revenues of $6.99 billion, representing a decrease of 0.9% year over year. The consensus EPS estimate for the quarter has undergone a downward revision of 2.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this ti ...

These stocks are trading at less than 15 times their expected future profits.Want a good income-producing investment to add to your portfolio? There are many high-yielding stocks you can buy right now at attractive discounts. And in addition to generating a lot of dividend income for your portfolio, these investments also have the potential to produce significant gains for you in the long run.Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck ...

Gilead Sciences (GILD) closed the latest trading day at $87.23, indicating a -1.05% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.92%. Meanwhile, the Dow experienced a drop of 0.96%, and the technology-dominated Nasdaq saw a decrease of 1.6%. The HIV and hepatitis C drugmaker's stock has climbed by 5.22% in the past month, exceeding the Medical sector's loss of 4.16% and the S&P 500's gain of 2.68%. Investors will be eagerly watching for the performance of Gilead Sci ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Loop Capital analyst Anthony Chukumba initiated coverage on Grocery Outlet Holding Corp. GO with a Hold rating and announced a price target of $17. Grocery Outlet shares closed at $16.45 on Wednesday. See how other analysts view this stock.Bernstein analyst Aaron Gal initiated coverage on Gilead Sciences, Inc. GILD with a ...